-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Role of Emicizumab in Acquired Hemophilia A

Program: Education Program
Session: Acquired Hemophilia A Diagnosis and Management
Hematology Disease Topics & Pathways:
Biological therapies, Bispecific Antibody Therapy, Therapies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Rebecca Kruse-Jarres, MD, MPH

University of Washington, Seattle, WA

Disclosures: Kruse-Jarres: Genentech: Consultancy, Other: research funding; Roche: Consultancy, Speakers Bureau; Regeneron: Consultancy; Biomarin: Speakers Bureau; Takeda: Speakers Bureau.

OffLabel Disclosure: emicizumab

See more of: Acquired Hemophilia A Diagnosis and Management
See more of: Education Program
<< Previous Presentation | Next Presentation